Nanopharmaceutical maker Tempo Pharma picks up $12M
Tempo Pharmaceuticals, a Cambridge, Mass., developer of new-drug formulations, raised $12.1 million in a first funding round. The company, which touts itself as a “nanopharmaceutical” maker, aims to improve the safety and effectiveness of existing drugs using engineered nanoparticles designed to home in on particular organs or tissues, then release two or more drugs in sequence. Tempo initially plans to focus on cancer.
Venrock and Polaris Venture Partners led the round, joined by Lux Capital and William Rastetter, former chairman of Biogen Idec. The company’s release is here; VentureWire has more here (subscription required).
Next Story: Google buys Feedburner for $100M
Previous Story: Rooftop Media raises $2.5M for “middle tail” comedy video site
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.